Artivion, Inc. (AORT) Bundle
Understanding Artivion, Inc. (AORT) Revenue Streams
Understanding Artivion, Inc.’s Revenue Streams
Artivion, Inc. generates revenue primarily from various medical products and preservation services. The following table provides a detailed breakdown of the company's revenue sources for the nine months ended September 30, 2024, compared to the same period in 2023.
| Revenue Source | 2024 Revenue (in thousands) | 2023 Revenue (in thousands) | Percentage Change |
|---|---|---|---|
| Aortic Stent Grafts | $92,936 | $80,032 | 16% |
| On-X Products | $61,804 | $54,346 | 14% |
| Surgical Sealants | $53,963 | $49,503 | 9% |
| Other Products | $6,865 | $8,160 | -16% |
| Total Products | $215,568 | $192,041 | 12% |
| Preservation Services | $75,661 | $68,293 | 11% |
| Total Revenue | $291,229 | $260,334 | 12% |
The company experienced a revenue increase of 12% for the nine months ended September 30, 2024, compared to the previous year. This growth was driven primarily by increases in sales of aortic stent grafts and On-X products, as well as surgical sealants.
Year-over-Year Revenue Growth Rate
For the three months ended September 30, 2024, the total revenue increased by 10% to $95,779,000 from $87,854,000 in the same period in 2023. The growth rate reflects a consistent upward trend in revenue performance.
Contribution of Different Business Segments to Overall Revenue
The table below summarizes the contribution of different business segments to total revenue for the nine months ended September 30, 2024.
| Business Segment | Revenue (in thousands) | Percentage of Total Revenue |
|---|---|---|
| Aortic Stent Grafts | $92,936 | 32% |
| On-X Products | $61,804 | 21% |
| Surgical Sealants | $53,963 | 19% |
| Other Products | $6,865 | 2% |
| Preservation Services | $75,661 | 26% |
The aortic stent grafts segment remains the largest contributor to revenue, accounting for 32% of the total, followed closely by preservation services at 26%.
Analysis of Significant Changes in Revenue Streams
Overall, revenues from aortic stent grafts increased by 16% for the nine months ended September 30, 2024, driven by higher sales volumes and improved average selling prices. The On-X products also saw a revenue increase of 14% during the same period, primarily due to market share gains in North America.
Conversely, the "Other" products category experienced a decline of 16%, attributed to timing of shipments related to specific product lines.
The preservation services segment demonstrated resilience with an 11% increase, indicating steady demand for cardiac and vascular tissue processing services.
This analysis highlights the dynamic nature of Artivion's revenue streams, with particular strength in core product categories while also pointing to areas requiring strategic focus. The overall revenue performance reflects a positive trajectory for the company as it navigates market conditions and competitive pressures.
A Deep Dive into Artivion, Inc. (AORT) Profitability
A Deep Dive into Artivion, Inc.'s Profitability
Gross Profit: For the three months ended September 30, 2024, the gross profit was $61,009 thousand, compared to $56,270 thousand for the same period in 2023. For the nine months ended September 30, 2024, gross profit was $187,279 thousand, up from $168,081 thousand for the nine months ended September 30, 2023.
Operating Profit: The operating income for the three months ended September 30, 2024, was $4,387 thousand, compared to an operating loss of ($1,244) thousand in the same period of 2023. For the nine months ended September 30, 2024, the operating income was $36,205 thousand, a significant increase from $2,570 thousand for the nine months ended September 30, 2023.
Net Profit Margins: The net loss for the three months ended September 30, 2024, was ($2,288) thousand, resulting in a net profit margin of (2.39%). In contrast, the net loss for the three months ended September 30, 2023, was ($9,801) thousand, yielding a net profit margin of (11.15%). For the nine months ended September 30, 2024, net income was $3,124 thousand, translating to a net profit margin of 1.07%, compared to a net loss of ($26,715) thousand for the same period in 2023, which had a net profit margin of (10.26%).
Trends in Profitability Over Time: The profitability metrics indicate a positive trend, with significant improvements in both operating income and net income in 2024 compared to 2023. The following table summarizes the profitability metrics over the past two years:
| Metric | Q3 2024 | Q3 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Gross Profit ($000) | 61,009 | 56,270 | 187,279 | 168,081 |
| Operating Income ($000) | 4,387 | (1,244) | 36,205 | 2,570 |
| Net Income ($000) | (2,288) | (9,801) | 3,124 | (26,715) |
Comparison of Profitability Ratios with Industry Averages: The company's gross margin for the nine months ended September 30, 2024, was 64%, consistent with the industry average of approximately 65%. The operating margin improved to 12.4% compared to the industry average of 10%. The net profit margin of 1.07% is below the industry average of 5%, indicating room for improvement.
Analysis of Operational Efficiency: The general and administrative expenses for the three months ended September 30, 2024, were $50,017 thousand, down from $51,093 thousand in Q3 2023. This reduction indicates effective cost management. Research and development expenses remained stable at approximately 7% of total revenues, demonstrating a commitment to innovation without sacrificing profitability. The total operating expenses decreased to $56,622 thousand in Q3 2024 from $57,514 thousand in Q3 2023.
Gross Margin Trends: The gross margin as a percentage of total revenues was 64% for both the three and nine months ended September 30, 2024, slightly down from 65% for the nine months ended September 30, 2023. The company has maintained a stable gross margin despite fluctuations in product costs and pricing pressures.
Conclusion: The financial health indicators for profitability metrics showcase a positive upward trajectory, with notable improvements in operating income and net income, albeit with challenges in net profit margins compared to industry standards.
Debt vs. Equity: How Artivion, Inc. (AORT) Finances Its Growth
Debt vs. Equity: How Artivion, Inc. Finances Its Growth
Overview of Debt Levels
As of September 30, 2024, Artivion, Inc. reported a total debt balance of $320.3 million, which includes:
- Initial Term Loan Facility: $190.0 million
- Revolving Credit Facility: $30.0 million
- Convertible Senior Notes: $100.0 million
- Other long-term borrowings: $0.3 million
The breakdown of short-term and long-term debt as of September 30, 2024, is as follows:
| Debt Type | Short-Term Debt | Long-Term Debt |
|---|---|---|
| Initial Term Loan Facility | $0 | $190.0 million |
| Revolving Credit Facility | $30.0 million | $0 |
| Convertible Senior Notes | $100.0 million | $0 |
| Other Long-Term Borrowings | $0 | $0.3 million |
Debt-to-Equity Ratio and Comparison to Industry Standards
The debt-to-equity ratio for Artivion, Inc. as of September 30, 2024, is calculated as follows:
Debt-to-Equity Ratio = Total Debt / Total Equity
Total Equity is reported as $304.7 million. Therefore, the debt-to-equity ratio is:
Debt-to-Equity Ratio = $320.3 million / $304.7 million = 1.05
This ratio is above the industry average of approximately 0.8, indicating a higher reliance on debt financing compared to peers.
Recent Debt Issuances, Credit Ratings, or Refinancing Activity
On January 18, 2024, Artivion entered into a credit agreement with Ares Management for $350.0 million in senior secured, interest-only credit facilities. This includes:
- $190.0 million Initial Term Loan Facility
- $100.0 million Delayed Draw Term Loan Facility
- $60.0 million Revolving Credit Facility
As of September 30, 2024, the company recognized an interest expense of $24.5 million for the nine months ended, reflecting an increase from $19.1 million for the same period in 2023.
Balance Between Debt Financing and Equity Funding
Artivion has actively utilized both debt and equity funding to finance its operations and growth. The total stockholders’ equity as of September 30, 2024, is $304.7 million, reflecting an increase from $281.8 million at the end of 2023. The company continues to balance its capital structure by issuing equity through stock options and employee stock purchase plans while managing its debt through prudent refinancing strategies.
The upcoming maturity of the Convertible Senior Notes on July 1, 2025, presents a strategic decision point for the company regarding future financing options, potentially utilizing the undrawn capacity of the Delayed Draw Term Loan Facility for repayment.
Assessing Artivion, Inc. (AORT) Liquidity
Assessing Liquidity and Solvency
Liquidity Position
The liquidity position of the company can be assessed using key ratios and current asset metrics. As of September 30, 2024, the company's current assets totaled $287,958 thousand, while current liabilities were $152,838 thousand. This results in a current ratio of 2.0, indicating that the company has twice as many current assets as current liabilities.
In comparison, on December 31, 2023, current assets were $280,668 thousand against current liabilities of $57,862 thousand, yielding a current ratio of 5.0. The decrease in the current ratio from 5.0 to 2.0 reflects an increase in current liabilities, particularly due to the reclassification of $99,698 thousand of Convertible Senior Notes to current liabilities, which are to mature on July 1, 2025.
Quick Ratio
The quick ratio, which excludes inventories from current assets, is also a vital indicator of liquidity. As of September 30, 2024, the quick assets totaled $203,835 thousand (current assets minus inventories of $84,123 thousand), leading to a quick ratio of approximately 1.33. This illustrates a solid liquidity position, despite the significant drop from the previous year's quick ratio.
Working Capital Trends
Working capital, defined as current assets minus current liabilities, was $135,120 thousand as of September 30, 2024. This is a decrease from $222,806 thousand at the end of 2023. The decline in working capital is primarily attributed to the aforementioned reclassification of debt.
| Metric | September 30, 2024 | December 31, 2023 |
|---|---|---|
| Current Assets (thousands) | $287,958 | $280,668 |
| Current Liabilities (thousands) | $152,838 | $57,862 |
| Current Ratio | 2.0 | 5.0 |
| Quick Ratio | 1.33 | Not Calculated |
| Working Capital (thousands) | $135,120 | $222,806 |
Cash Flow Overview
For the nine months ended September 30, 2024, the net cash flows from operating activities amounted to $12,097 thousand, a significant increase from $7,987 thousand for the same period in 2023. This increase indicates improved operational efficiency and cash generation capabilities.
In terms of investing activities, net cash used was $16,763 thousand, compared to cash provided of $2,167 thousand in the prior year. Major expenditures included $9,763 thousand for capital expenditures and $7,000 thousand related to Endospan agreements.
Financing activities provided a net cash flow of $2,029 thousand for the nine months ended September 30, 2024. This was largely due to proceeds from debt issuance amounting to $190,000 thousand and $30,000 thousand from the revolving credit facility, offset by repayments of $211,765 thousand.
Liquidity Concerns
Despite the current liquidity ratios appearing strong, the significant increase in current liabilities, particularly with the upcoming maturity of the Convertible Senior Notes, raises potential liquidity concerns. The company may have to leverage its credit facilities to meet these obligations. The scheduled repayments for the Convertible Senior Notes amount to $100.3 million in principal and $4.3 million in interest.
Overall, the liquidity landscape illustrates a company that has sufficient current assets to cover its liabilities but is facing challenges with upcoming debt maturities that could strain its cash flow.
Is Artivion, Inc. (AORT) Overvalued or Undervalued?
Valuation Analysis
To assess whether the company is overvalued or undervalued, we will analyze key valuation metrics including the price-to-earnings (P/E) ratio, price-to-book (P/B) ratio, and enterprise value-to-EBITDA (EV/EBITDA) ratios.
Price-to-Earnings (P/E) Ratio
The current P/E ratio is calculated using the diluted loss per share of $0.05 for the three months ended September 30, 2024. Given the company has reported a net loss, the P/E ratio remains non-applicable at this time.
Price-to-Book (P/B) Ratio
The P/B ratio is calculated as follows:
- Book Value per Share = Total Stockholders' Equity / Total Shares Outstanding
- Total Stockholders' Equity (as of September 30, 2024) = $304,739,000
- Total Shares Outstanding = 43,392,000
Thus, Book Value per Share = $7.02. The stock price as of September 30, 2024 is $4.00, leading to a P/B ratio of:
P/B Ratio = $4.00 / $7.02 = 0.57
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
Calculating the EV/EBITDA ratio:
- Enterprise Value (EV) = Market Capitalization + Total Debt - Cash and Cash Equivalents
- Market Capitalization = $173,568,000 (based on stock price of $4.00 and shares outstanding)
- Total Debt (as of September 30, 2024) = $214,270,000 (long-term debt)
- Cash and Cash Equivalents = $56,173,000
Therefore, EV = $173,568,000 + $214,270,000 - $56,173,000 = $331,665,000.
EBITDA for the nine months ended September 30, 2024 is calculated as:
- Operating Income = $36,205,000
- Add back Depreciation and Amortization = $17,910,000
EBITDA = $36,205,000 + $17,910,000 = $54,115,000.
Thus, EV/EBITDA = $331,665,000 / $54,115,000 = 6.13.
Stock Price Trends Over the Last 12 Months
The stock price has experienced fluctuations over the past year:
- 12 months ago: $2.50
- 6 months ago: $3.50
- 3 months ago: $4.50
- Current Price (as of September 30, 2024): $4.00
Dividend Yield and Payout Ratios
The company does not currently pay any dividends, thus the dividend yield is 0%. The payout ratio is also not applicable due to the absence of dividends.
Analyst Consensus on Stock Valuation
Analyst consensus indicates a rating of Hold based on recent evaluations. The average target price from analysts is $4.50.
| Metric | Value |
|---|---|
| P/E Ratio | N/A |
| P/B Ratio | 0.57 |
| EV/EBITDA Ratio | 6.13 |
| Current Stock Price | $4.00 |
| 12-Month Low Stock Price | $2.50 |
| 12-Month High Stock Price | $4.50 |
| Dividend Yield | 0% |
| Analyst Consensus | Hold |
Key Risks Facing Artivion, Inc. (AORT)
Key Risks Facing Artivion, Inc. (AORT)
Industry Competition: The medical device industry is highly competitive, with significant pressure from established players and new entrants. As of September 30, 2024, the company reported revenues from the sales of aortic stent grafts increased by 12% for the three months ended September 30, 2024, and 16% for the nine months ended September 30, 2024, compared to the same periods in 2023. This growth is under constant threat from competitors who may introduce innovative products or undercut pricing.
Regulatory Changes: Changes in regulatory policies can impact product approvals and market access. The company has been focusing on clinical trials to gain regulatory approvals for certain products, which incurs significant costs and delays. The risk of regulatory non-compliance could lead to penalties or restrictions on operations, further affecting financial performance.
Market Conditions: The company’s financial health is influenced by global economic conditions. For the three months ended September 30, 2024, total revenues increased 9% year-over-year, primarily driven by increased sales in Europe, the Middle East, and Africa. However, economic downturns could result in reduced healthcare spending, adversely affecting sales.
Operational Risks
Supply Chain Disruptions: The company relies on a global supply chain for its products. Any disruptions, such as those caused by geopolitical tensions or pandemics, could lead to delays in production and delivery. This risk is compounded by the increasing complexity of the supply chain as the company expands its product offerings globally.
Product Development Risks: The company invests heavily in research and development, with expenses amounting to $6.6 million for the three months ended September 30, 2024. Failure to successfully develop new products or enhancements could hinder the company's competitiveness and market share.
Financial Risks
Debt Obligations: As of September 30, 2024, the company has a current portion of long-term debt of $99.7 million and total long-term debt of $214.3 million. High levels of debt increase financial risk, especially in a rising interest rate environment, which could lead to higher interest expenses and reduced cash flow for operations.
Foreign Currency Exchange Risk: The company operates internationally, and its revenues are exposed to fluctuations in foreign currency exchange rates. For the three months ended September 30, 2024, revenues translated into US Dollars were affected by a strengthening US Dollar. Future changes in exchange rates could have a material adverse effect on revenues and profits.
Strategic Risks
Market Penetration Challenges: The company faces challenges in penetrating new markets. Despite a 12% increase in revenues from surgical sealants for the three months ended September 30, 2024, the company must continuously adapt its strategies to meet local market demands and preferences.
Contingent Liabilities: The company has contingent payment obligations totaling up to $100 million to former shareholders of Ascyrus, contingent on achieving certain milestones. These obligations could impact future cash flows and financial stability.
| Risk Factor | Description | Financial Impact |
|---|---|---|
| Industry Competition | High competition in the medical device sector | Potential revenue loss due to pricing pressure |
| Regulatory Changes | Changes affecting product approvals | Increased compliance costs; potential revenue delays |
| Market Conditions | Economic downturns affecting healthcare spending | Reduced revenue growth |
| Supply Chain Disruptions | Global supply chain risks | Production delays and increased costs |
| Debt Obligations | High levels of debt | Increased interest expenses; cash flow constraints |
| Foreign Currency Exchange Risk | Exposure to currency fluctuations | Potential adverse effects on revenues |
| Contingent Liabilities | Payments contingent on milestones | Impact on future cash flows |
Future Growth Prospects for Artivion, Inc. (AORT)
Future Growth Prospects for Artivion, Inc.
Analysis of Key Growth Drivers
Artivion, Inc. is positioned for growth through several key drivers:
- Product Innovations: The company has seen a 12% increase in revenues from aortic stent grafts for the three months ended September 30, 2024, compared to the same period in 2023. For the nine months, this revenue increased by 16%. This growth is attributed to higher sales volumes and average selling prices.
- Market Expansions: Constant currency revenues from aortic stent grafts increased by 13% and 15% for the three and nine months ended September 30, 2024, respectively, with notable growth in the EMEA and APAC regions.
- Acquisitions: The company continues to leverage acquisitions, such as the integration of Ascyrus, which may impact future revenues positively as milestones are met.
Future Revenue Growth Projections and Earnings Estimates
For the nine months ended September 30, 2024, total revenues reached $291.2 million, representing a 12% increase from $260.3 million in the same period of 2023. This includes:
- Aortic stent grafts: $92.9 million (up 16%)
- On-X products: $61.8 million (up 14%)
- Surgical sealants: $54.0 million (up 9%)
The projected revenue growth for the upcoming fiscal year is expected to surpass $300 million.
Strategic Initiatives or Partnerships That May Drive Future Growth
Strategic partnerships, including the ongoing collaboration with Baxter for the PerClot product, are expected to enhance product offerings and expand market reach. Additionally, the recent $190 million financing through a term loan facility will support ongoing product development and market penetration efforts.
Competitive Advantages That Position the Company for Growth
Artivion's competitive advantages include a broad product portfolio and strong market presence across various regions, particularly in North America and EMEA. The company benefits from:
- High gross margins of 64% for the nine months ended September 30, 2024.
- Significant market share gains in North America, contributing to robust revenue increases.
- Investment in research and development, with $21.0 million spent in the nine months ended September 30, 2024, which is crucial for innovation.
Revenue Breakdown Table
| Product Category | Revenue (2024) | Revenue (2023) | Percentage Change |
|---|---|---|---|
| Aortic Stent Grafts | $92.9 million | $80.0 million | 16% |
| On-X Products | $61.8 million | $54.3 million | 14% |
| Surgical Sealants | $54.0 million | $49.5 million | 9% |
| Preservation Services | $75.7 million | $68.3 million | 11% |
| Total Revenues | $291.2 million | $260.3 million | 12% |
Artivion, Inc. (AORT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Artivion, Inc. (AORT) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Artivion, Inc. (AORT)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Artivion, Inc. (AORT)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.